• EMAIL
  • PRINT
  • PDF
  • Bookmark and Share

Education

  • J.D., Suffolk University Law School, 2013
  • Ph.D., Pennsylvania State University, Chemistry, 2008
  • B.S., University of the Sciences in Philadelphia, Chemistry, magna cum laude, 2001
  • A.S., Middlesex County College, Biology, 1999

Bar Admissions

  • Massachusetts
  • U.S. Patent & Trademark Office

Memberships & Affiliations

Pro-Bono litigator for the Family Law Project for Battered Women

Co-Chair of Boston Patent Law Association New Lawyers, Law Students & Technology Specialists Committee

American Intellectual Property Law Association (AIPLA)

American Chemical Society (ACS)

Michael J. DeGrazia, Ph.D.

  • |
Partner
  • T: 617.449.6585
    F: 617.892.4076

Dr. DeGrazia is a partner in the Intellectual Property and Information Technology practice group.

Dr. DeGrazia’s practice focuses on chemical, pharmaceutical, and biotechnologies, with particular emphasis on small molecule drugs. His primary areas of focus cover the drafting, filing, and prosecution of US and foreign patent applications; global portfolio strategy and management; freedom-to operate (FTO) assessments; patentability and infringement analyses; competitive landscape investigations; patent issues related to licensing, acquisition, and financing such as initial public offerings (IPO); and strategic counseling.

Dr. DeGrazia is well versed in life cycle management and patent term extension. His technical experience most notably includes new chemical entities, compositions/formulations, dispersions, polymorphs, processes, patient stratifications, new medical uses, and clinical trial data protection/inclusion.

In addition to counseling and prosecution, he also has experience in patent litigation, in particular Abbreviated New Drug Application (ANDA) cases arising under the Hatch-Waxman Act and post-grant proceedings. Dr. DeGrazia’s clients include small and large companies, academic institutions, and individual inventors. Their technologies span from investigatory and those undergoing clinical review to post-market approval and billion-dollar biotech and molecular drug products.

Dr. DeGrazia earned his Ph.D. in organic chemistry from the Penn State University where he studied the synthesis of fluorescently labeled small molecules for high-throughput screening and control of intracellular pathways. Prior to graduate work, he also investigated new coupling routes for modification of the anticancer drug paclitaxel (Taxol®).

Professional Recognition
Oral Advocate and Distinguished Brief Award (Suffolk Law School)
Research award for accomplishments in organic chemistry (Penn State University)
Dan H. Waugh Memorial Teaching Award (Penn State University)
Geiger Fellowship (Penn State University)
Louis A. Reber Memorial Research Award (Penn State University)
American Institute of Chemists Award (University of the Sciences)

Speaking

05/02/18